Agios Pharmaceuticals (NASDAQ: AGIO)
Agios Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Agios Pharmaceuticals Company Info
Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
News & Analysis
4 Reasons Agios' Oncology Deal Should Please Investors
Agios' newly revamped business strategy is an extreme departure from the company's original mission, but it's a great deal for shareholders.
Why Agios Pharmaceuticals Stock Is Soaring Today
Investors applauded the company's planned sale of its oncology portfolio.
2 Mid-Cap Healthcare Stocks to Buy Now
These drugmakers are in the sweet spot to provide market-beating returns.
Got $1,000? Buy These 4 Cancer Stocks
These four cancer therapeutics stocks are poised to experience long-term growth.
Agios Pharmaceuticals Raised $294 Million to Fight Cancer and Rare Genetic Diseases: What It Means for Investors
The cash will help the biotech get to profitability.
Could These Be the Next 2 Biotech Buyouts?
If GlaxoSmithKline's recent splurge signals a new round of acquisitions, these stocks could be next.
Why Alcoa, Merck, and Agios Pharmaceuticals Jumped Today
On a positive day for the market, these stocks outperformed. Find out why.
Why Agios Pharmaceuticals Shares Jumped 37.8% in January
The company's got some big catalysts coming.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.